Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences is convening an annual general meeting of shareholders on September 8, 2026 at 10:00 a.m. (Shanghai time) in Shanghai. Shareholders will vote on an ordinary resolution to remove Ms. Xin Liu as a director with immediate effect. The board cites efforts to enhance its corporate governance framework and optimize board size and composition, and recommends voting FOR the resolution.
Holders of ordinary shares of par value US$0.0001 per share on July 27, 2026 (Shanghai time) may attend and vote in person or by proxy, with proxies due by 4:00 p.m. (Shanghai time) on September 6, 2026. Holders of American depositary shares on July 27, 2026 (Eastern Time) must submit voting instructions to Citibank, N.A. by 10:00 a.m. (Eastern Time) on September 1, 2026. Meeting materials and the Form 20-F annual report for the year ended December 31, 2025 are available on NovaBridge’s and the SEC’s websites.
NovaBridge Biosciences has adopted a new 2026 Omnibus Share Incentive Plan, effective July 13, 2026, as the successor to its prior share incentive plans. The plan initially reserves up to 11,960,000 ordinary shares, equivalent to 5,200,000 American Depositary Shares, plus unused and returning shares from predecessor plans.
The share pool is subject to an annual evergreen increase each January 1 from 2027 through 2036, up to the lesser of 3% of shares outstanding on the prior December 31 or a smaller amount set by the board. The plan runs for ten years and supports a wide range of awards, including options, share appreciation rights, restricted shares, share units and other share- or cash-based awards for employees, consultants and outside directors. Related disclosure is incorporated by reference into existing F-3 and S-8 registration statements.
NovaBridge Biosciences reported that Chief Commercial Officer Mark Arnold Hagler received a grant of 949,050 2025 Employee Share Options, each representing a right to buy American Depositary Shares (ADS) at an exercise price of $1.93 per ADS. These options have an expiration date of July 8, 2036 and, according to the vesting terms, become exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. The options relate to Ordinary Shares that may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. Following this award, Hagler holds 949,050 derivative securities of this type directly.
NovaBridge Biosciences reported that General Counsel Lin Liwei Lorraine received a grant of 254,780 2025 Employee Share Options, each representing a right to buy American Depositary Shares at an exercise price of 1.9300 per ADS. The options expire on 2036-07-08 and relate to an equivalent number of underlying Ordinary Shares represented by ADSs. The grant vests over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance in three equal annual installments thereafter.
NovaBridge Biosciences reported that Chief Executive Officer Srishti Gupta received a grant of 3,000,000 employee share options. These options give the right to buy Ordinary Shares at an exercise price of $2.01 per ADS-equivalent and expire on July 6, 2036. The award vests in four equal annual installments beginning on the first anniversary of July 1, 2026, and Gupta now holds 3,000,000 such options directly.
NovaBridge Biosciences director and Chief Executive Officer Srishti Gupta has filed an initial statement of ownership as an insider of the company. This Form 3 filing does not list any equity transactions or derivative positions and provides no reportable holdings or recent trades for this insider.
NovaBridge Biosciences senior executive Xu Cong Claire reported option exercises and a share sale. On July 4, 2026, she exercised derivative awards, converting 5,405 Restricted Share Units, represented by 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares at a conversion price of $0.00 per share.
On July 6, 2026, she completed an open-market sale of 4,485 Ordinary Shares at an average price of $0.89 per share, equivalent to an ADS sales price of $2.04. Following these transactions, she directly holds 298,101 Ordinary Shares, which the filing states are represented by 129,609 ADSs.
NovaBridge Biosciences director Fu Wei received equity-based compensation awards. On June 29, 2026, Fu Wei was granted 1,010,100 Restricted Share Units, each representing a contingent right to receive one American Depositary Share (ADS). These RSUs vest in equal annual installments on June 29, 2027 and June 29, 2028.
On the same date, Fu Wei was also granted three tranches of 2025 Employee Share Options covering 1,087,720, 1,087,720 and 725,140 underlying Ordinary Shares at an exercise price of $2.45 per share, expiring on June 29, 2036. Each option tranche vests, if at all, in eight equal quarterly installments after the issuer’s ADS 30-trading-day weighted average price reaches $8.00, $12.00 and $16.00, respectively.
NovaBridge Biosciences is implementing a major leadership transition. The company appointed Srishti Gupta, MD MPP as Chief Executive Officer and board member, effective July 1, 2026, succeeding Xi-Yong (Sean) Fu, who resigns as CEO and director on June 30, 2026 but will remain as an advisor during the transition.
Dr. Gupta is an experienced physician-executive and former CEO of Idorsia Pharmaceuticals, with nearly two decades in biopharma, global health, and strategy, including a long tenure at McKinsey & Company. As CEO, she plans to advance givastomig toward registration, expand the Visara-led ophthalmology franchise around VIS-101, and build strategic partnerships.
The filing also notes additional changes: two directors, Emmett T. Cunningham Jr. and Sean Cao, will resign from the board on June 30, 2026, with Dr. Cunningham joining the Scientific Advisory Board, and President Mark Hagler will step down from that role on July 1, 2026 while continuing as Chief Commercial Officer.
NovaBridge Biosciences director and Chief Business Development Officer Cao Sean Wuxiong received new equity awards. He was granted 181,290 employee share options to buy Ordinary Shares (via American Depositary Shares) at an exercise price of $1.53 per ADS, expiring on June 22, 2036. These options vest in eight equal quarterly installments only after the 30-trading-day weighted average price of the company’s ADS is at or above $8.00.
He also received 181,280 restricted share units, each representing a contingent right to receive one ADS. These RSUs vest over four years, with one-fourth vesting on September 3, 2026 and the remainder vesting ratably over the following 12 quarters.